Simone Song
Oprichter bij ORI Capital Investment Advisory Hong Kong Ltd.
Vermogen: 15 M $ op 30-04-2024
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Allan Bradley | M | 64 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | 14 jaar |
Mary Szela | F | 60 |
TriSalus Operating Life Sciences, Inc.
TriSalus Operating Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology TriSalus Operating Life Sciences, Inc. develops infusion systems for the interventional radiology and oncology markets. Its infusion systems are designed to deliver embolic agents through a micro-catheter with an expandable tip that collapses in forward flow and expands the vessel wall in reverse flow to increase targeted delivery, minimize reflux, and reduce damage to healthy tissue. The company was founded by Aravind Arepally and James E. Chomas in 2011 and is headquartered in Westminster, CO. | 6 jaar |
Bobby Gaspar | M | 60 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 9 jaar |
Tan Li | F | 60 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Marc Dunoyer | M | 71 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 6 jaar |
Timothy James Rink | M | 78 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Christian Itin | M | 59 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Timothy Nigel Carl Wells | M | 62 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Charles Rowland | M | 65 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 6 jaar |
Alan Bradley | M | 64 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | - |
Erwin Boos | M | 46 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Douglas Fearon | M | - |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Gang Song | M | - |
ORI Capital Investment Advisory Hong Kong Ltd.
ORI Capital Investment Advisory Hong Kong Ltd. Investment ManagersFinance ORI Capital Investment Advisory Hong Kong Ltd (ORI Capital) is a venture capital firm in Hong Kong. The firm was founded by Simone Song in 2015. The firm is headquartered in Hong Kong. | 7 jaar |
Joanne Beck | M | 63 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 6 jaar |
Anil Singhal | M | 72 |
TriSalus Operating Life Sciences, Inc.
TriSalus Operating Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology TriSalus Operating Life Sciences, Inc. develops infusion systems for the interventional radiology and oncology markets. Its infusion systems are designed to deliver embolic agents through a micro-catheter with an expandable tip that collapses in forward flow and expands the vessel wall in reverse flow to increase targeted delivery, minimize reflux, and reduce damage to healthy tissue. The company was founded by Aravind Arepally and James E. Chomas in 2011 and is headquartered in Westminster, CO. | 6 jaar |
Jon Ellis | M | 57 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 6 jaar |
Dicky To | M | - |
ORI Capital Investment Advisory Hong Kong Ltd.
ORI Capital Investment Advisory Hong Kong Ltd. Investment ManagersFinance ORI Capital Investment Advisory Hong Kong Ltd (ORI Capital) is a venture capital firm in Hong Kong. The firm was founded by Simone Song in 2015. The firm is headquartered in Hong Kong. | 5 jaar |
Elaine Yang | F | - |
ORI Capital Investment Advisory Hong Kong Ltd.
ORI Capital Investment Advisory Hong Kong Ltd. Investment ManagersFinance ORI Capital Investment Advisory Hong Kong Ltd (ORI Capital) is a venture capital firm in Hong Kong. The firm was founded by Simone Song in 2015. The firm is headquartered in Hong Kong. | 7 jaar |
Volker Germaschewski | M | - |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Otto Cheung | M | - |
ORI Capital Investment Advisory Hong Kong Ltd.
ORI Capital Investment Advisory Hong Kong Ltd. Investment ManagersFinance ORI Capital Investment Advisory Hong Kong Ltd (ORI Capital) is a venture capital firm in Hong Kong. The firm was founded by Simone Song in 2015. The firm is headquartered in Hong Kong. | - |
Cathy Choi | F | - |
ORI Capital Investment Advisory Hong Kong Ltd.
ORI Capital Investment Advisory Hong Kong Ltd. Investment ManagersFinance ORI Capital Investment Advisory Hong Kong Ltd (ORI Capital) is a venture capital firm in Hong Kong. The firm was founded by Simone Song in 2015. The firm is headquartered in Hong Kong. | - |
Edward Tung | M | - |
ORI Capital Investment Advisory Hong Kong Ltd.
ORI Capital Investment Advisory Hong Kong Ltd. Investment ManagersFinance ORI Capital Investment Advisory Hong Kong Ltd (ORI Capital) is a venture capital firm in Hong Kong. The firm was founded by Simone Song in 2015. The firm is headquartered in Hong Kong. | 5 jaar |
Gillian Zhou | F | - |
ORI Capital Investment Advisory Hong Kong Ltd.
ORI Capital Investment Advisory Hong Kong Ltd. Investment ManagersFinance ORI Capital Investment Advisory Hong Kong Ltd (ORI Capital) is a venture capital firm in Hong Kong. The firm was founded by Simone Song in 2015. The firm is headquartered in Hong Kong. | 3 jaar |
Gene R. McGrevin | M | 81 |
TriSalus Operating Life Sciences, Inc.
TriSalus Operating Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology TriSalus Operating Life Sciences, Inc. develops infusion systems for the interventional radiology and oncology markets. Its infusion systems are designed to deliver embolic agents through a micro-catheter with an expandable tip that collapses in forward flow and expands the vessel wall in reverse flow to increase targeted delivery, minimize reflux, and reduce damage to healthy tissue. The company was founded by Aravind Arepally and James E. Chomas in 2011 and is headquartered in Westminster, CO. | 12 jaar |
Jasper Clube | M | 56 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Diane Parks | F | 71 |
TriSalus Operating Life Sciences, Inc.
TriSalus Operating Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology TriSalus Operating Life Sciences, Inc. develops infusion systems for the interventional radiology and oncology markets. Its infusion systems are designed to deliver embolic agents through a micro-catheter with an expandable tip that collapses in forward flow and expands the vessel wall in reverse flow to increase targeted delivery, minimize reflux, and reduce damage to healthy tissue. The company was founded by Aravind Arepally and James E. Chomas in 2011 and is headquartered in Westminster, CO. | 5 jaar |
Alicia Secor | F | 62 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | - |
John L. Tullis | M | - |
TriSalus Operating Life Sciences, Inc.
TriSalus Operating Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology TriSalus Operating Life Sciences, Inc. develops infusion systems for the interventional radiology and oncology markets. Its infusion systems are designed to deliver embolic agents through a micro-catheter with an expandable tip that collapses in forward flow and expands the vessel wall in reverse flow to increase targeted delivery, minimize reflux, and reduce damage to healthy tissue. The company was founded by Aravind Arepally and James E. Chomas in 2011 and is headquartered in Westminster, CO. | - |
Kerry Hicks | M | 64 |
TriSalus Operating Life Sciences, Inc.
TriSalus Operating Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology TriSalus Operating Life Sciences, Inc. develops infusion systems for the interventional radiology and oncology markets. Its infusion systems are designed to deliver embolic agents through a micro-catheter with an expandable tip that collapses in forward flow and expands the vessel wall in reverse flow to increase targeted delivery, minimize reflux, and reduce damage to healthy tissue. The company was founded by Aravind Arepally and James E. Chomas in 2011 and is headquartered in Westminster, CO. | - |
James Mulé | M | 72 |
ORI Capital Investment Advisory Hong Kong Ltd.
ORI Capital Investment Advisory Hong Kong Ltd. Investment ManagersFinance ORI Capital Investment Advisory Hong Kong Ltd (ORI Capital) is a venture capital firm in Hong Kong. The firm was founded by Simone Song in 2015. The firm is headquartered in Hong Kong. | - |
Nigel Clark | M | - |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Glenn Alfons Friedrich | M | - |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Alf Gunnar Martin Nicklasson | M | 69 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | 7 jaar |
Sean Murphy | M | 71 |
TriSalus Operating Life Sciences, Inc.
TriSalus Operating Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology TriSalus Operating Life Sciences, Inc. develops infusion systems for the interventional radiology and oncology markets. Its infusion systems are designed to deliver embolic agents through a micro-catheter with an expandable tip that collapses in forward flow and expands the vessel wall in reverse flow to increase targeted delivery, minimize reflux, and reduce damage to healthy tissue. The company was founded by Aravind Arepally and James E. Chomas in 2011 and is headquartered in Westminster, CO. | 3 jaar |
Mark P. Valadao | M | - |
ORI Capital Investment Advisory Hong Kong Ltd.
ORI Capital Investment Advisory Hong Kong Ltd. Investment ManagersFinance ORI Capital Investment Advisory Hong Kong Ltd (ORI Capital) is a venture capital firm in Hong Kong. The firm was founded by Simone Song in 2015. The firm is headquartered in Hong Kong. | - |
James Geraghty | M | 69 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 6 jaar |
Mats Wahlström | M | 70 |
TriSalus Operating Life Sciences, Inc.
TriSalus Operating Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology TriSalus Operating Life Sciences, Inc. develops infusion systems for the interventional radiology and oncology markets. Its infusion systems are designed to deliver embolic agents through a micro-catheter with an expandable tip that collapses in forward flow and expands the vessel wall in reverse flow to increase targeted delivery, minimize reflux, and reduce damage to healthy tissue. The company was founded by Aravind Arepally and James E. Chomas in 2011 and is headquartered in Westminster, CO. | 7 jaar |
Frank Thomas | M | 54 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 6 jaar |
Paul Kellam | M | - |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Mark Rothera | M | 61 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 3 jaar |
Benjamin Auspitz | M | 51 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | - |
Andrea Spezzi | M | - |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 6 jaar |
Nicolas Koebel | M | - |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 7 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigd Koninkrijk | 26 | 60.47% |
Hongkong | 9 | 20.93% |
Verenigde Staten | 8 | 18.60% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Simone Song
- Persoonlijk netwerk